· Sales increased by 3 percent, to SEK 30.5 (29.5) million. Adjusted for exchange-rate effects the increase was 6 percent.

· Gross income amounted to SEK 20.6 (20.5) million and the gross margin to 67 percent (69).

· Operating income amounted to SEK 5.4 (5.4) million.

· Net income for the Group was SEK 6.2 (6.1) million.

· Earnings per share amounted to SEK 0.34 (0.33).

· The equity/assets ratio increased to 83 percent (78).

· Sale of the shares in Cellartis AB has led to a capital gain of SEK 2.4 million.

· Sales approval has been obtained for ICSI" in the USA.

· A patent concerning the use of alanyl-glutamine in media for embryos and stem cells has been approved in the USA.

· Powerful measures have been taken during the period with regard to marketing, R&D and the expansion of production capacity.

May 10, 2005
Kungsbacka, Sweden

Magnus Nilsson
CEO

Questions should be addressed to:
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.